|Dr. Mark Erlander Ph.D.||CEO & Director||783.23k||N/A||1960|
|Mr. James E. Levine||Chief Financial Officer||585.16k||N/A||1971|
|Ms. Vicki Kelemen||Chief Operating Officer||512.24k||N/A||N/A|
|Dr. Tod Smeal Ph.D.||Chief Scientific Officer?||N/A||N/A||N/A|
|Ms. Elizabeth Anderson||VP of Fin. & Admin.||N/A||N/A||N/A|
|Mr. Charles Monahan R.Ph.||Sr. VP of Regulatory Affairs||N/A||N/A||N/A|
Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; metastatic colorectal cancer that is in clinical trials; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company's TROV-053 is also in Phase II clinical trial in combination with Zytiga for metastatic castration-resistant prostate cancer. The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.
Cardiff Oncology, Inc.’s ISS Governance QualityScore as of May 1, 2022 is 4. The pillar scores are Audit: 6; Board: 3; Shareholder Rights: 3; Compensation: 8.